AshishM.KamatMDMBBS, FACS

Surgical Oncology

Professor & Attending Surgeon, Director of Urologic Oncology Fellowship, University Texas MD Anderson Cancer Center

Dr. Kamat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2001 - 2003
West Virginia UniversityChief Residency, Urology, 2000 - 2001
West Virginia UniversityResidency, Urology, 1997 - 2000
West Virginia UniversityResidency, Surgery, 1995 - 1997
Seth G.S. Medical CollegeClass of 1994

PubMed

46 citations
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Ekaterina Laukhtina, Sung Ryul Shim, Keiichiro Mori, David D'Andrea, Francesco Soria
European Urology Oncology. 2021-11-06
19 citations
Current Use and Promise of Urinary Markers for Urothelial Cancer.
William Tabayoyong, Ashish M. Kamat
Current Urology Reports. 2018-10-17
211 citations
ZKSCAN3 Is a Master Transcriptional Repressor of Autophagy
Santosh Chauhan, Jinesh G. Goodwin, Swati Chauhan, Ganiraju C. Manyam, Jing Wang
Molecular Cell. 2013-04-11

Journal Articles

Seminars Article New Horizons in Bladder Cancer Research
Stephen B Williams, Ashish M Kamat, ScienceDirect
Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer—Reply
Ashish M Kamat, Stephen B Williams, JAMA
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
Ashish M Kamat, Yair Lotan, European Urology
Comparing Survival Outcomes and Costs Associated with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive Bladder Cancer
Jacques G Baillargeon, Douglas S Tyler, Stephen B Williams, Anthony J Senagore, Todd A Swanson, Ashish M Kamat, Eduardo Orihuela, JAMA
Join now to see all

Lectures

Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent foll...
2019 ASCO Annual Meeting - 6/1/2019

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018September 2018
Recommendations for Follow-up of Muscle-Invasive Bladder Cancer Patients: A Consensus by the International Bladder Cancer NetworkFebruary 2018
Contribution of Bladder Cancer Pathology Assessment in Planning Clinical TrialsFebruary 2018

Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve SurvivalNovember 6th, 2024
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastMay 17th, 2024
Clinical Trials for Bladder CancerSeptember 3rd, 2022
Join now to see all